Search

Displaying results 4371 - 4380 of 10000 in total
  1. Drug

    LCP-AtorFen

    go.drugbank.com/drugs/DB05769
    Investigational

    LCP-AtorFen is designed to be a once daily tablet offering a powerful and safe treatment of high cholesterol levels, addressing three primary cardiovascular risk factors: low density lipoprotein cholesterol … LCP-AtorFen is a fixed-dose combination therapy for the treatment of high cholesterol levels combining atorvastatin (the active ingredient of Lipitor®) and the lowest dose of fenofibrate without food effect

  2. Drug

    ADH-1

    go.drugbank.com/drugs/DB05485
    Investigational

    As many tumors become more aggressive, invasive, and malignant, researchers have found that N-cadherin is expressed in greater amounts, making it an important target for developing anti-cancer treatments … ADH-1 may have utility in a wide variety of cancers as N-cadherin is overexpressed in a variety of tumors.

    Synonyms: l-cysteinamide, n-acetyl-l-cysteinyl-l-histidyl-l-alanyl-l-valyl-, cyclic (1-5)-disulfide
  3. Drug

    Nicergoline

    go.drugbank.com/drugs/DB00699
    Approved

    An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. It has been suggested to ameliorate cognitive deficits in cerebrovascular disease.

    Categories: Heterocyclic Compounds with 4 or More Rings
  4. Drug

    RESP301

    go.drugbank.com/drugs/DB16497
    Investigational

    Additionally, RESP301 was investigated in a withdrawn trial (NCT04842331) for preventing viral exposure and transmission of COVID-19 and in a not yet recruiting trial (NCT04386070) for preventing pulmonary … RESP301 was under investigation in clinical trials for various conditions.

    Categories: Experimental Unapproved Treatments for COVID-19
  5. Drug

    Enzastaurin

    go.drugbank.com/drugs/DB06486
    Investigational

    Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form of

  6. Drug

    Leriglitazone

    go.drugbank.com/drugs/DB15021
    Investigational

    Leriglitazone is under investigation in clinical trial NCT03917225 (A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients).

  7. Drug

    Phenoxypropazine

    go.drugbank.com/drugs/DB09251
    ApprovedWithdrawn

    It was marketed as an antidepressant in 1961 but was later withdrawn in 1966 because of its hepatotoxic potential. … Phenoxypropazine is a non-selective and irreversible monoamine oxidase enzyme inhibitor (MAOI), belonging to the _hydrazine_ chemical class.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  8. Drug

    Patupilone

    go.drugbank.com/drugs/DB03010
    Investigational

    Epothilone B is a 16-membered macrolide that mimics the biological effects of taxol.

  9. Drug

    Levopropoxyphene

    go.drugbank.com/drugs/DB06793
    ApprovedWithdrawn

    Levopropoxyphene is a stereoisomer of propoxyphene in the form of 2S, 3R enantiomer. It was sold as an antitussive, but it was removed from the market in the 70s. … [T133] Levopropoxyphene was developed by Lilly and FDA approved on March 21st, 1962. This drug presented different dosages and it was administered as a capsule or suspension.

  10. Drug

    Phenacetin

    go.drugbank.com/drugs/DB03783
    ApprovedWithdrawn

    Phenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).

    Categories: Analgesics, Non-Narcotic